ImmuCell (ICCC) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmuCell (ICCC) has outperformed Alpha Teknova (TKNO) over the past year, gaining 133.3% versus a gain of 77.4%. Over five years, ICCC leads with a +18.7% price change compared with -63.6% for TKNO. Alpha Teknova is the larger company by market cap ($480.0 million vs $99.3 million), about 4.8 times the size.
ImmuCell converts more of its revenue into profit, with a net margin of -3.8% versus -42.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICCC | TKNO |
|---|---|---|
| Share price | $10.92 | $7.63 |
| Market cap | $99.28M | $479.95M |
| 1-day change | -2.41% | -2.30% |
| YTD return | +77.56% | +100.79% |
| 1-year return | +133.33% | +77.44% |
| 5-year return | +18.70% | -63.63% |
| P/E ratio (TTM) | 57.47 | — |
| EPS (TTM) | $0.19 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $27.64M | $40.52M |
| Revenue growth (YoY) | +4.34% | +7.35% |
| Net income (latest FY) | $-1.04M | $-17.26M |
| Gross margin | 41.40% | 33.17% |
| Operating margin | 5.97% | -41.90% |
| Net margin | -3.76% | -42.59% |
| 52-week high | $12.10 | $9.48 |
| 52-week low | $4.67 | $1.91 |
| Distance from 52-week high | -9.75% | -19.51% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +28.83% |
| Average volume | 13.44K | 437.31K |
| Shares outstanding | 9.09M | 62.90M |
| Employees | 73 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Alpha Teknova is about 4.8 times larger than ImmuCell by market value ($479.95M vs $99.28M).
- ICCC has outperformed TKNO by 55.9 percentage points over the past year.
- ImmuCell is more profitable, keeping -3.8 cents of every revenue dollar as net income versus -42.6 cents for Alpha Teknova.
About ImmuCell
ICCC stock →ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 73 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
ICCC vs TKNO FAQ
Which is bigger, ImmuCell or Alpha Teknova?
Alpha Teknova (TKNO) is larger, with a market capitalization of $479.95M compared with $99.28M for ImmuCell (ICCC).
Which stock has performed better over the past year, ICCC or TKNO?
ICCC returned +133.33% over the past 12 months, compared with +77.44% for TKNO (price return, excluding dividends). Past performance does not predict future results.
Are ImmuCell and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.